undamentalytics Newsletter
Sign in

Embecta Corp. (EMBC) stock

Add to watchlist

Add holding +

NASDAQ: EMBC Nasdaq Health Care Supplies Next results ~November 25, 2026

C+ Fundamentals grade

Embecta Corp. is a US-listed company in the health care supplies industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($0.02) was left out of our combined valuation (it is 0.00x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Price vs value

Under review: our cash-flow value ($0.02) was left out of our combined valuation (it is 0.00x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating. We'll show the comparison once resolved.

Embecta Corp. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 1 selling4 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds135 adding, 148 cuttingOf 48 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Embecta files

Where Embecta stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.02bn, down 7.6% on a year earlier, a steeper fall than the 3.4% decline a quarter earlier. Free-cash-flow margin rose to 16.2% from 12.0% a year earlier. Operating margin widened to 21.9% from 19.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 3 financial-health checks.

Our model value for Embecta is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 25, 2026 (estimated)

Embecta Corp.'s trailing-twelve-month revenue fell 7.6% year on year, with a free-cash-flow margin of 16.2%. Where it stands out: free-cash-flow margin of 16.2% ranks 1 of 13 health care supplies companies we cover. Where it lags: long-term debt as % of assets of 104.0% ranks 9 of 9 health care supplies companies we cover.

Our discounted-cash-flow model values the business at ~$0.0 per share in the base case (—–$7.3 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 24.4% while net income grew 4.7%: a 20pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Embecta Corp.'s latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 7.6% over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 82% and a beta of 0.5 against the S&P 500.
  • Growth easing. The growth rate is 4.2 points lower than a quarter earlier.
  • Gross margin slipping. Gross margin is down 3.7 points on a year ago.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 104.0% ranks 9 of 9 health care supplies companies we cover (median 15.4%).
  • Below peers: change in growth rate. Change in growth rate of -4.2pp ranks 10 of 13 health care supplies companies we cover (median -0.3pp).

Latest results: FY2026 Q3

Filed August 7, 2026
Earnings per share
$0.56 against an average estimate of $0.27: beat by 111.3%
Revenue
$272m, down 8.1% on a year earlier
Share reaction
+42.6% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500
Guidance given
reported Revenues $1,015m to $1,035m (fiscal year 2026); reported Revenue Growth (%) growth -6.1% to -4.2% (fiscal year 2026)
Next report
November 25, 2026; average EPS estimate $0.29

Embecta's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.0%
  • 1 week-9.0%
  • 1 month+9.6%
  • This year-46.9%
  • 1 year-52.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1B
Operating margin
21.9%
Net margin
8.6%
EPS (TTM, diluted)
$1.48

Growth

Revenue growth
−7.6%
Change in growth rate
−4.2 pts
Share count change
+0.6%

Cash

Free cash flow (TTM)
$165M
FCF margin
16.2%
Stock pay % of revenue
2.5%

Earnings

Last results
August 7, 2026
Next results (est.)
November 24, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Embecta Corp. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($0.02) was left out of our combined valuation (it is 0.00x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Our value per share comes from a discounted-cash-flow model of Embecta Corp.'s free cash flow after stock-based pay ( $72.9M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Embecta Corp. as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.88 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$0.0 Left out: out of range vs price (0.00x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$27 ~$23–$45 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Embecta Corp. with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$25.02$13.40$13.08$13.66$6.19
Market value$1.4bn$774m$763m$805m$367m
+ Net debt (− = net cash)$1.3bn$1.3bn$1.3bn$1.2bn$1.3bn
Enterprise value$2.8bn$2.1bn$2.1bn$2.0bn$1.6bn
Multiples
Price / sales 1.3x0.7x0.7x0.7x0.4x
Price / earnings 6.4x11.0x9.7x8.4x4.2x
Price / free cash flow 3.7x18.8x38.3x4.4x2.2x
EV / EBITDA 8.1x8.2x10.3x7.1x6.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

70 /100

Moderate moat

How hard Embecta's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 10 / 20

    Net income has been a median 6.9% of total assets over 5 years.

  • Pricing power 18 / 20

    Gross margin has been a median 66.4%, moving by 3.8 percentage points (standard deviation) across 5 years.

  • Durability 16 / 20

    Operating margin has been a median 19.2%; its worst year was 14.9%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 5 of 5 years, at a median 12.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (75 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 25, 2026, before the open. Analysts expect revenue of $270m and EPS of $0.29 (range $0.28 to $0.31) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.83 −38% $1.0bn −5%
Next $1.76 −4% $1.1bn +6%

Next year's EPS estimate has moved +1.3% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +14.9% on 90 days ago. In the last 30 days, 3 analysts raised Embecta Corp.'s forecast and 0 cut it.

Consensus EPS forecast Embecta Corp., last 90 days
$1.50 $1.60 $1.70 $1.80 $1.90 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.60 Current fiscal year, 60 days ago: $1.83 Current fiscal year, 30 days ago: $1.83 Current fiscal year, 7 days ago: $1.83 Current fiscal year, Now: $1.83 $1.83 Next fiscal year, 90 days ago: $1.74 Next fiscal year, 60 days ago: $1.76 Next fiscal year, 30 days ago: $1.76 Next fiscal year, 7 days ago: $1.76 Next fiscal year, Now: $1.76 $1.76

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.60$1.74
60 days ago $1.83$1.76
30 days ago $1.83$1.76
7 days ago $1.83$1.76
Now $1.83$1.76

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.27 $0.56 +111.3%
Mar 2026 $0.42 $0.27 −35.3%
Dec 2025 $0.67 $0.71 +6.0%
Sept 2025 $0.46 $0.50 +9.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 7, 2026
  • Reported Revenues fiscal year 2026 $1,015m to $1,035m GAAP Maintained
    “Reported Revenues $1,015 - $1,035 $1,015 - $1,035” source
  • Adjusted Earnings per Diluted Share fiscal year 2026 $1.80 to $1.90 Non-GAAP Raised
    “Adjusted Earnings per Diluted Share $1.80 - $1.90 $1.55 - $1.75” source
  • Adjusted Operating Margin (%) fiscal year 2026 23.5% to 24% Non-GAAP Raised
    “Adjusted Operating Margin (%) 23.50% - 24.00% 22.25% - 23.25%” source
  • Reported Revenue Growth (%) fiscal year 2026 -6.1% growth to -4.2% growth GAAP Maintained
    “Reported Revenue Growth (%) (6.1)% - (4.2)% (6.1)% - (4.2)%” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Embecta Corp.'s revenue by +4.1% next year and +3.0% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+4.9%, weight 49%) , management guidance (+4.9%, weight 22%) and the company's own record (+2.0%, weight 29%) . How the weights are set.

Analyst recommendations

4 analysts, Nov 2026
Buy00%
Hold375%
Sell125%

Monthly trend

  1. Nov 2026314
  2. Oct 2026314

Counts of recommendations published by analysts covering Embecta Corp., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
12.5%
of tradable shares
Days to cover
5.82
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
92%
of shares
Held by insiders
2.0%
of shares
Employees
1,850
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −52.1%

$12.91 on October 31, 2025 to $6.19

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.0bn −7.6%
Net margin 7.6% 8.6% +13.3%
P/E multiple 9.1x 4.2x −53.9%
Share count 59m 59m −0.6%

Biggest factor: p/e multiple.

Last 3 years −57.1%

$14.44 on November 3, 2023 to $6.19

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.0bn −8.5%
Net margin 4.2% 8.6% +102.6%
P/E multiple 17.5x 4.2x −76.1%
Share count 57m 59m −3.2%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 2023202420252026 to date
Return
EMBC−23%+14%−40%−47%
Industry peers (median)+38%−13%−13%−7%
S&P 500+26%+25%+18%+11%
Months that ended higher
EMBC50%42%17%46%
S&P 50067%75%75%46%
Largest fall from a high during the year
EMBC−60%−47%−55%−77%
S&P 500−10%−8%−19%−9%

Worst fall since March 22, 2022: 93% from March 22, 2022 to May 19, 2026. Getting back needed a 1309% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.89 – $14.17
From 52-week high
−56.3%
vs 50-day average
+7.6%
vs 200-day average
−2.7%
Volatility (1 year)
82%
Beta vs S&P 500
0.45

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±22.0%
After a week
5 up, 7 down
typical move ±25.2%
After a month
6 up, 6 down
typical move ±30.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 +42.6% +0.6% +45.7% +58.9%
May 5, 2026 −61.5% +2.2% −63.1% −63.0%
February 5, 2026 −4.3% +0.6% −11.9% −17.5%
November 25, 2025 −14.1% +1.6% −18.4% −16.9%
August 8, 2025 +22.9% +0.6% +32.1% +48.5%
May 9, 2025 −6.7% +3.2% −9.6% −22.8%
February 6, 2025 −4.3% −0.6% −11.3% −22.4%
November 26, 2024 +42.9% +0.2% +42.3% +44.7%
August 9, 2024 +2.9% +0.5% −1.0% +8.5%
May 9, 2024 +38.7% +0.7% +38.3% +20.4%
February 9, 2024 −15.7% +0.5% −18.5% −21.8%
November 21, 2023 +7.9% +0.2% +10.8% +15.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Embecta Corp. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Embecta Corp.
$1B $1.1B $1.1B $1.2B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $1.1B Revenue (TTM), FY24 Q1: $1.1B Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $1.1B Revenue (TTM), FY24 Q4: $1.1B Revenue (TTM), FY25 Q1: $1.1B Revenue (TTM), FY25 Q2: $1.1B Revenue (TTM), FY25 Q3: $1.1B Revenue (TTM), FY25 Q4: $1.1B Revenue (TTM), FY26 Q1: $1.1B Revenue (TTM), FY26 Q2: $1B Revenue (TTM), FY26 Q3: $1B $1B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $1.1B
FY24 Q1 $1.1B
FY24 Q2 $1.1B
FY24 Q3 $1.1B
FY24 Q4 $1.1B
FY25 Q1 $1.1B
FY25 Q2 $1.1B
FY25 Q3 $1.1B
FY25 Q4 $1.1B
FY26 Q1 $1.1B
FY26 Q2 $1B
FY26 Q3 $1B
Revenue growth, TTM YoY Embecta Corp.
-10% -5% 0% 5% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -0.8% Revenue growth, TTM YoY, FY24 Q1: 0.6% Revenue growth, TTM YoY, FY24 Q2: 1.3% Revenue growth, TTM YoY, FY24 Q3: 0.5% Revenue growth, TTM YoY, FY24 Q4: 0.2% Revenue growth, TTM YoY, FY25 Q1: -1.3% Revenue growth, TTM YoY, FY25 Q2: -4.7% Revenue growth, TTM YoY, FY25 Q3: -1.5% Revenue growth, TTM YoY, FY25 Q4: -3.8% Revenue growth, TTM YoY, FY26 Q1: -2.5% Revenue growth, TTM YoY, FY26 Q2: -3.4% Revenue growth, TTM YoY, FY26 Q3: -7.6% -7.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -0.8%
FY24 Q1 0.6%
FY24 Q2 1.3%
FY24 Q3 0.5%
FY24 Q4 0.2%
FY25 Q1 -1.3%
FY25 Q2 -4.7%
FY25 Q3 -1.5%
FY25 Q4 -3.8%
FY26 Q1 -2.5%
FY26 Q2 -3.4%
FY26 Q3 -7.6%
Operating margin (TTM) Embecta Corp.
10% 15% 20% 25% 30% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 19.8% Operating margin (TTM), FY24 Q1: 15.9% Operating margin (TTM), FY24 Q2: 14.3% Operating margin (TTM), FY24 Q3: 14.9% Operating margin (TTM), FY24 Q4: 14.9% Operating margin (TTM), FY25 Q1: 13.5% Operating margin (TTM), FY25 Q2: 16.1% Operating margin (TTM), FY25 Q3: 19.2% Operating margin (TTM), FY25 Q4: 22.4% Operating margin (TTM), FY26 Q1: 27.5% Operating margin (TTM), FY26 Q2: 25.8% Operating margin (TTM), FY26 Q3: 21.9% 21.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 19.8%
FY24 Q1 15.9%
FY24 Q2 14.3%
FY24 Q3 14.9%
FY24 Q4 14.9%
FY25 Q1 13.5%
FY25 Q2 16.1%
FY25 Q3 19.2%
FY25 Q4 22.4%
FY26 Q1 27.5%
FY26 Q2 25.8%
FY26 Q3 21.9%
FCF margin (TTM) Embecta Corp.
-10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 3.7% FCF margin (TTM), FY24 Q1: -2.7% FCF margin (TTM), FY24 Q2: 0.8% FCF margin (TTM), FY24 Q3: 1.2% FCF margin (TTM), FY24 Q4: 1.8% FCF margin (TTM), FY25 Q1: 2.6% FCF margin (TTM), FY25 Q2: 3.7% FCF margin (TTM), FY25 Q3: 12.0% FCF margin (TTM), FY25 Q4: 16.9% FCF margin (TTM), FY26 Q1: 19.1% FCF margin (TTM), FY26 Q2: 19.6% FCF margin (TTM), FY26 Q3: 16.2% 16.2%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 3.7%
FY24 Q1 -2.7%
FY24 Q2 0.8%
FY24 Q3 1.2%
FY24 Q4 1.8%
FY25 Q1 2.6%
FY25 Q2 3.7%
FY25 Q3 12.0%
FY25 Q4 16.9%
FY26 Q1 19.1%
FY26 Q2 19.6%
FY26 Q3 16.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Embecta took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $1.1B
  2. Cost of revenue $404M · 37.4%
  3. Gross profit $677M · 62.6%
  4. Research and development $37.3M · 3.5%
  5. Selling, general and admin $332M · 30.7%
  6. Other operating costs $65.4M · 6.1%
  7. Operating income $242M · 22.4%
  8. Income tax $40.9M · 3.8%
  9. Interest and other $106M · 9.8%
  10. Net income $95.4M · 8.8%

Shares of revenue. Source: Embecta's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 1,086 1,165 1,130 1,121 1,123 1,080 1,019
Gross profit 763 800 775 750 735 677 601
EBITDA 525 530 341 254 203 283 268
Operating income 487 492 310 222 167 242 224
Net income 428 415 224 70 78 95 88
Diluted EPS $7.50 $7.28 $3.89 $1.22 $1.34 $1.62 $1.48
Growth (year on year)
Revenue — +7.4% −3.1% −0.8% +0.2% −3.8% −7.6%
EBITDA — +1.0% −35.6% −25.5% −20.1% +39.3% +7.6%
Operating income — +1.1% −37.1% −28.5% −24.7% +45.1% +5.5%
Net income — −3.0% −46.1% −68.5% +11.2% +21.8% +4.7%
Diluted EPS — −2.9% −46.6% −68.6% +9.8% +20.9% +4.0%
Margins
Gross margin 70.3% 68.7% 68.6% 66.9% 65.5% 62.6% 59.0%
EBITDA margin 48.3% 45.5% 30.2% 22.7% 18.1% 26.2% 26.3%
Operating margin 44.8% 42.2% 27.4% 19.8% 14.9% 22.4% 21.9%
Net margin 39.4% 35.6% 19.8% 6.3% 7.0% 8.8% 8.6%
Free-cash-flow margin 42.1% 36.0% 34.4% 3.7% 1.8% 16.9% 16.2%
Cash flow
Cash from operations 499 456 412 68 36 192 174
Capital spending 42 37 24 27 16 9 10
Free cash flow 457 420 389 41 20 182 165
Stock-based pay 13 13 19 22 26 32 25
Free cash flow after stock pay 444 407 370 20 −6 151 139
Balance sheet
Cash 0 0 331 326 268 226 215
Total debt 0 0 1,645 1,636 1,601 1,417 1,469
Net debt (negative = net cash) 0 0 1,314 1,310 1,334 1,191 1,255
Diluted shares 57m 57m 57m 58m 58m 59m 59m
Returned to shareholders
Dividends 0 0 9 34 35 35 27
Total returned 0 0 9 34 35 35 27

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $1.3bn
Short-term assets $705mLonger-term assets $560m
What it owes, and who funded it · $420m
Short-term liabilities $420mShareholders' equity $-613m
  • Short-term assets cover short-term liabilities $705m of assets due within a year against $420m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $215m of cash against $1.5bn of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $174m of operating cash flow against $1.5bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Embecta Corp.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$27.2M
Returned to shareholders
17%
of free cash flow
Diluted share count
+0.6%
year over year
Total shareholder yield
7.8%
dividends 7.8% + buybacks 0.0% of market value
Dividend payout ratio
31%
of net income paid out
R&D spending
2.0%
of revenue
Sales & admin spending
31.3%
of revenue
Days sales outstanding
65 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated EMBC UFPT ICUI ORGO NVST WST Median
Revenue, last 12 months $1.0bn $632m $2.2bn $457m $2.9bn $3.4bn $1.0bn
Revenue growth, last 12 months −7.6% 7.3% −9.0% 6.5% 11.9% 12.6% 3.4%
Revenue growth, 3-year average −2.9% 17.8% −2.0% 0.0% 3.4% 5.1% 0.0%
Revenue growth, latest quarter −8.1% 15.1% 0.5% −56.7% 7.1% 8.7% 0.6%
Gross margin 59.0% 28.5% 39.1% 75.9% 55.2% 37.6% 52.9%
Operating margin 21.9% 15.3% 3.3% −7.8% 9.6% 23.0% 3.3%
Operating margin, 3-year average 18.7% 15.4% 2.2% −5.2% −10.9% 20.8% 2.2%
Net margin 8.6% 11.4% 1.4% −18.4% 3.3% 18.8% 1.4%
Cash from operations / revenue 17.1% 11.3% 10.9% 7.0% 10.6% 19.3% 10.6%
Free-cash-flow margin 16.2% 9.0% 6.7% 4.6% 8.7% 13.3% 6.7%
Free-cash-flow margin, 3-year average 9.8% 10.5% 5.2% −1.4% 10.0% 12.4% 9.8%
Stock pay / revenue 2.5% 1.6% 2.5% 3.1% 1.4% 0.8% 2.5%
Change in share count 0.6% 0.2% 2.5% 1.7% −3.3% −1.5% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth -7.6% 3.4% 9 of 13
Change in growth rate Growth -4.2pp -0.3pp 10 of 13
Gross margin Profitability 59.0% 52.9% 5 of 13
Operating margin Profitability 21.9% 3.3% 2 of 13
Net margin Profitability 8.6% 1.4% 5 of 13
Free-cash-flow margin Cash generation 16.2% 6.7% 1 of 13
Stock pay as % of revenue Cash generation 2.5% 2.5% 7 of 13
Long-term debt as % of assets Balance sheet 104.0% 15.4% 9 of 9
Change in share count Balance sheet 0.6% 0.1% 9 of 12
Days sales outstanding Balance sheet 65 days 65 days 5 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to September 30, 2025
Products and services
Line of business Revenue Share YoY
Pen Needles $784M 72.6% ▼ 7.1%
Safety $138M 12.8% ▲ 6.5%
Syringes $125M 11.5% ▼ 1.3%
Manufacturing Facility $19.9M 1.8% ▲ 55.5%
Other $14M 1.3% ▲ 35.9%
Geography
Region Revenue Share YoY
United States $579M 53.6% ▼ 4.6%
Outside the US $501M 46.4% ▼ 2.8%

From Embecta Corp.'s 10-K filed November 25, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$165M
Institutions reporting
316
Shares held vs prior quarter
▼ 16.9%
Positions opened / closed
56 / 73

Top buyers and sellers, Q2 2026: 135 institutions bought and 148 sold ; the biggest buyer was Brigade Capital Management, LP (+1.5M shares) and the biggest seller Blackrock, Inc (−4.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $15M 4.6M 9.1% ▼ 49.8%
Yacktman Asset Management LP $14.1M 4.3M 8.5% ▲ 17.5%
Vanguard Capital Management LLC $8.3M 2.6M 5.1% ▼ 0.3%
Deerfield Management Company, L.P. $8.3M 2.5M 5.0% 0.0%
Jefferies Financial Group Inc. $7.7M 2.4M 4.7% 0.0%
Ameriprise Financial Inc $6.6M 2.0M 4.0% ▲ 154.9%
Morgan Stanley $6.5M 2.0M 4.0% ▲ 227.4%
State Street Corp $5.3M 1.6M 3.2% ▼ 36.7%
Geode Capital Management, LLC $5.2M 1.6M 3.2% ▲ 8.8%
Brigade Capital Management, LP $4.9M 1.5M 3.0% New
Goldman Sachs Group Inc $3.8M 1.2M 2.3% ▲ 55.3%
Krensavage Asset Management, LLC $3.7M 1.1M 2.2% ▲ 54.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Embecta Corp.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $557,850 4 trades by 4 insiders, last 12 months Insider sales History → $37,003 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $520,847 net buying
Insider Date Trade Shares Price Value
Morris Milton Mayo Director September 4, 2026 Sell 6,293 $5.88 $37,003
Hombach Robert J. Director August 12, 2026 Buy 45,000 $4.97 $223,650
Mann Jeffrey Z Pres, Pharm Svc&Prod Mgmt, CLO August 12, 2026 Buy 20,000 $4.99 $99,800
Elguicze Jacob SVP and CFO August 12, 2026 Buy 20,000 $4.67 $93,400
Kurdikar Devdatt President and CEO August 12, 2026 Buy 30,000 $4.70 $141,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 24, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • May 5, 2026
  • February 5, 2026
  • November 25, 2025
  • August 8, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Embecta Corp. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Embecta Corp. in brief

What does Embecta Corp. do?
Embecta Corp. is a US-listed company in the health care supplies industry. Its financial year ends in September.
What is Embecta Corp.'s stock ticker?
Embecta Corp. trades under the ticker EMBC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Embecta Corp.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Embecta Corp. reported revenue of $1B, 7.6% lower than a year earlier, according to its SEC filings.
What is Embecta Corp.'s free cash flow?
Embecta Corp.'s free-cash-flow margin is 16.2% of revenue over the trailing twelve months, ranking 1 of the 13 health care supplies companies we cover.
Who are Embecta Corp.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Yacktman Asset Management LP and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Embecta Corp.'s market cap?
On November 2, 2026, Embecta Corp.'s market capitalisation was about $367M, with a price-to-earnings ratio of 4.2 and net debt of $1.3B. Market figures come from third-party market data and may be delayed.
Does Embecta Corp. pay a dividend?
Yes: Embecta Corp. paid $27.2M in dividends over the trailing twelve months, a dividend yield of 7.76% and a payout ratio of 31.1%.
Who are Embecta Corp.'s competitors?
In our Health Care Supplies peer group, the companies closest to Embecta Corp. are UFP Technologies Inc, ICU Medical Inc, Organogenesis Holdings Inc., Envista Holdings Corp and West Pharmaceutical Services. The side-by-side comparison below sets their revenue, margins and growth against Embecta Corp.'s.
Are insiders buying or selling Embecta Corp. stock?
Over the last 12 months, Embecta Corp.'s directors and officers reported 4 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Embecta Corp.'s next earnings date?
Around November 25, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Embecta Corp. announces its own schedule.